Related Experiment Video
Updated: Sep 16, 2026
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome:
Freida P Raj1, Harry Boo2, Ashley Kenney3
1Obstetrics and Gynecology, Drexel College of Medicine, Philadelphia, USA.
Objective:
This retrospective cohort study aims to evaluate whether semaglutide use in patients with polyendocrine metabolic ovarian syndrome (PMOS) is associated with an increased risk of mood disorders compared to patients treated with metformin by utilizing a large, propensity-matched dataset from TriNetX.
Methodology:
The TriNetX platform was used to conduct a retrospective cohort study with International Classification of Diseases, 10th Revision (ICD-10) codes to generate inclusion and exclusion criteria. After propensity matching, each cohort consisted of 20,535 patients, for a total sample size of 41,070. Cohort 1 (patients with PMOS and on metformin) and Cohort 2 (patients with PMOS and on semaglutide) were evaluated for outcomes of new-onset major depressive disorder, generalized anxiety disorder, insomnia, and suicidal ideation that emerged after the start of the medication of interest.
Results:
There was no statistically significant difference in generalized anxiety disorder and suicidal ideation associated with semaglutide use as compared to metformin in women with PMOS. However, there was a minor statistically significant difference in the rates of insomnia and major depressive disorder.
Conclusions:
These results suggest that psychiatric considerations alone should not preclude the use of semaglutide in PMOS management. Ongoing mental health screening and follow-up remain essential for all patients with PMOS, regardless of treatment choice.